The World Health Organization (WHO) was informed of an outbreak of pneumonia from an unknown cause detected in Wuhan, China on the 31st of December 2019. After finding out the cause, today we know that the infectious agent was a virus from the coronavirus family, named SARS CoV-2 that causes a respiratory disease called Covid-19. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. The genome of SARS CoV-2 encodes four main structural proteins: Nucleocapsid (N), Spike (S), Membrane (M), and Envelope (E). Two of these proteins appear to be important antigenic sites for the development of assays for detecting COVID-19, the Spike, and Nucleocapsid protein. Exonbio has developed a comprehensive range of recombinant proteins to help the scientific community accelerate COVID-19/SARS-CoV-2 research and development. SARS CoV-2 Reagent Antibodies
Figure 1: Schematic of 2019-nCoV Spike protein. The spike protein consists of S1 and S2 domains. S1 domain contains N-Terminal Domain (NTD), Receptor Binding Domain (RBD) and C-Terminal Domain (SD1 + SD2). The S2 domain is responsible for fusion and contains the heptad repeat (HR1), Central Helix (CH) and Connector Domain (CD). Cleavage sites are indicated with arrows.
